Researchers from MIT and Massachusetts General Hospital have developed “Sybil,” an AI tool that can detect the risk of a patient developing lung cancer within six years, reports Mary Kekatos for ABC News. “Sybil was trained on low-dose chest computer tomography scans, which is recommended for those between ages 50 and 80 who either have a significant history of smoking or currently smoke,” explains Kekatos.
Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.
A study by researchers from the Broad Institute and others have found that cancer in humans and dogs share genomic similarities, reports Nicole Karlis for Salon. “Specifically, the study identified 18 genetic mutations that are likely a primary driver of the cancer in canine patients, eight of which overlapped with so-called "hotspots" in human cancers,” writes Karlis.
MIT researchers have discovered an RNA-guided DNA-cutting enzyme in eukaryotes, reports Science. “The researchers speculate that eukaryotic cells may have gained the newly identified editing genes from transposable elements—so-called jumping genes—they received from bacteria,” writes Science.
MIT researchers have identified a new biological editing system that could “potentially be even more precise than CRISPR gene editing,” reports Laura Baisas for Popular Science. The new system, based on a protein called Fanzor, is “the first programmable RNA-guided system discovered in eukaryotes,” Baisas notes.
A study led by Steven Hyman, director of the Stanley Center for Psychiatric Research at the Broad Institute, found that the AKAP11 gene has a significant impact on a person’s risk for bipolar disorder, reports Kirstie Ganobsik for HealthDay. “This work is exciting because it's the first time we've had a gene with large-effect mutations for bipolar disorder," says Hyman.
Soledad O’Brien spotlights how researchers from MIT and Massachusetts General Hospital developed a new artificial intelligence tool, called Sybil, that an accurately predict a patient’s risk of developing lung cancer. “Sybil predicted with 86 to 94 percent accuracy whether a patient would develop lung cancer within a year,” says O’Brien.
Researchers at MIT have developed a new nanoparticle sensor that can detect cancerous proteins through a simple urine test. “The researchers designed the tests to be done on a strip of paper, similar to the at-home COVID tests everyone became familiar with during the pandemic,” writes Lambert. “They hope to make it as affordable and accessible to as many patients as possible.”
NBC News highlights how researchers from MIT and MGH have developed a new AI tool, called Sybil, that can “accurately predict whether a person will develop lung cancer in the next year 86% to 94% of the time.” NBC News notes that according to experts, the tool "could be a leap forward in the early detection of lung cancer.”
Researchers at the McGovern and Broad Institutes have developed a bacterial "nanosyringe" that can inject large proteins into specific cells in the body, which could lead to safer and more effective treatments for a variety of conditions, including cancer, reports Michael Le Page for New Scientist. “The fact that this can load a diversity of different payloads of different sizes makes it unique amongst protein delivery devices,” says graduate student Joseph Kreitz.
Ingrid Wickelgren at Scientific American highlights a new study from researchers at the McGovern and Broad Institutes, in which they used a bacterial ‘nanosyringe’ to inject large proteins into human cells. “The syringe technology also holds promise for treating cancer because it can be engineered to attach to receptors on certain cancer cells,” writes Wickelgren.
Aera Therapeutics, founded by Prof. Feng Zhang, is working to “debut a type of protein nanoparticle that it believes can be used to ferry all sorts of genetic medicines around the body,” reports Lisa Jarvis for Bloomberg.
Prof. Feng Zhang founded Aera Therapeutics, a startup working to deliver curative genetic medicine to hard-to-reach parts of the body, reports Ryan Cross for The Boston Globe. “If Aera’s approach works in people, it could broaden the reach of genetic therapies, which currently have limited clinical applications – partly because there aren’t enough methods for getting those medicines to hone in on the right cells,” writes Cross.
Researchers at MIT and Massachusetts General Hospital have developed “Sybil” – an artificial intelligence tool that can predict the risk of a patient developing lung cancer within six years, reports Mallika Marshall for CBS Boston.
MIT researchers have developed a new AI tool called Sybil that could help predict whether a patient will get lung cancer up to six years in advance, reports Pranshu Verma for The Washington Post. “Much of the technology involves analyzing large troves of medical scans, data sets or images, then feeding them into complex artificial intelligence software,” Verma explains. “From there, computers are trained to spot images of tumors or other abnormalities.”